1. Mutate & conjugate : a method for rapid in-cell validation of epigenetic targets
- Author
-
Thomas, Adam, Conway, Stuart, and Bush, Jacob
- Subjects
Medicinal chemistry ,Chemical biology - Abstract
A bottleneck in the drug discovery process is target validation. Target validation is the process of demonstrating that engagement with a cellular target is linked to the desired therapeutic effect, confirming that the target has a key role in the disease phenotype. Incomplete or incorrect target validation can lead to costly failures at the later stages of drug development. Consequently, techniques that enable rapid and robust target validation are of great value to those seeking to discover new medicines. The advantage of using small molecule ligands over genetic knockdowns, in target validation, is the temporal control over the "knockdown". In this approach, reactive covalent fragments have been combined with a cysteine mutant of the target protein. It was hypothesised that covalent inhibition would circumvent the need to optimise ligand affinity, accelerating probe development, while also offering increased residency times that could potentially act as a functional knockdown, thus providing information on the function of the target. The BET bromodomain-containing protein, BRD4, was chosen for proof-of-concept studies. Bromodomains are epigenetic 'reader' modules that recognise and bind to acetylated lysines on histone tails, and signal for the recruitment of protein complexes responsible for gene regulation. Owing to the conserved nature of the BET bromodomains, the development of single-domain selective ligands has proved challenging. Consequently, development of ligands that enable the probing of single domain function are highly sought after. Herein, the application of a 'mutate & conjugate' approach to enable selective biological probing of BRD4(1) is reported. A structurally stable and functioning mutant, BRD4(1)L94C, was designed, expressed, and validated. Using a structure-guided, and a fragment-based approach, ~270 reactive fragments were screened for C94 labelling. Subsequent fragments were developed and exhibited selective inhibition of BRD4(1)L94C over BRD4(1)WT in an AlphaScreen™ assay. Clickable analogues were used to evaluate proteome-wide selectivity, leading to the discovery of a covalent fragment with exquisite in-cell selectivity for BRD4(1)L94C. Finally, a 'mutate & conjugate' strategy was applied to the development of selective protein degraders. This work shows that the combination of reactive fragments and site-directed-mutagenesis could be applied to rapidly develop chemical probes for target validation studies.
- Published
- 2022